Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Fatal submassive hepatic necrosis associated with tyrosine-methionine-aspartate-aspartate-motif mutation of hepatitis B virus after long-term lamivudine therapy.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 1 Aug 2001

Kim J W, Lee H S, Woo G H, Yoon J H, Jang J J, Chi J G, Kim C Y

Abstract excerpt

We present a case of infection with lamivudine-resistant mutant hepatitis B virus (HBV) that fatally exacerbated hepatitis following the emergence of HBV with mutations in the tyrosine-methionine-aspartate-aspartate (YMDD) motif in an immunocompetent patient who was receiving long-term lamivudine therapy. Restriction fragment length polymorphism analysis showed that the YMDD-motif mutant was the predominant form...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amino Acid Motifs
Share to Drug Resistance, Microbial

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Fatal Outcome

Share to Hepatitis B, Chronic

Share to Immunocompetence

Share to Lamivudine

Share to Necrosis

Share to Reverse Transcriptase Inhibitors

Source

Identifiers

PMID: 11438912
DOI: 10.1086/321879

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Fatal submassive hepatic necrosis associated with tyrosine-methionine-aspartate-aspartate-motif mutation of hepatitis B virus after long-term lamivudine therapy.PMID 11438912Read ↗

Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy.Semantic proximity Read ↗

Emergence of YMDD motif mutants of hepatitis B virus during lamivudine treatment of immunocompetent type B hepatitis patients.Semantic proximity Read ↗

Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B.Semantic proximity Read ↗

Severe acute exacerbation of liver disease may reduce or delay emergence of YMDD motif mutants in long-term lamivudine therapy for hepatitis B e antigen-positive chronic hepatitis B.Semantic proximity Read ↗

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy.Semantic proximity Read ↗

Clinical outcome and virologic profiles of severe hepatitis B exacerbation due to YMDD mutations.Semantic proximity Read ↗

Clinical features of chronic hepatitis B patients with YMDD mutation after lamivudine therapy.Semantic proximity Read ↗

Management of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B.Semantic proximity Read ↗

Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection.Semantic proximity Read ↗

Pre-existing YMDD mutants in treatment-naïve patients with chronic hepatitis B are not selected during lamivudine therapy.Semantic proximity Read ↗

Interferon therapy for flare-up of hepatitis B virus infection after emergence of lamivudine-induced YMDD motif mutant.Semantic proximity Read ↗

Virus and transaminase levels determine the emergence of drug resistance during long-term lamivudine therapy in chronic hepatitis B.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.